[go: up one dir, main page]

WO2004075922A3 - Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisation et lesdits agents de liaison - Google Patents

Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisation et lesdits agents de liaison Download PDF

Info

Publication number
WO2004075922A3
WO2004075922A3 PCT/FR2004/000413 FR2004000413W WO2004075922A3 WO 2004075922 A3 WO2004075922 A3 WO 2004075922A3 FR 2004000413 W FR2004000413 W FR 2004000413W WO 2004075922 A3 WO2004075922 A3 WO 2004075922A3
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
active substance
compounds
binding
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2004/000413
Other languages
English (en)
Other versions
WO2004075922A2 (fr
Inventor
Antony R Rees
Patrick Mouchet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Publication of WO2004075922A2 publication Critical patent/WO2004075922A2/fr
Publication of WO2004075922A3 publication Critical patent/WO2004075922A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé comprenant au moins une substance active et au moins un vecteur, lesdits substance active et vecteur étant reliés par un agent de liaison, l'utilisation dudit composé pour la préparation d'une composition pharmaceutique, ladite composition pharmaceutique. La présente invention concerne également lesdits agents de liaison.
PCT/FR2004/000413 2003-02-24 2004-02-24 Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisation et lesdits agents de liaison Ceased WO2004075922A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR03/02242 2003-02-24
FR0302242A FR2851471B1 (fr) 2003-02-24 2003-02-24 Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison

Publications (2)

Publication Number Publication Date
WO2004075922A2 WO2004075922A2 (fr) 2004-09-10
WO2004075922A3 true WO2004075922A3 (fr) 2005-01-20

Family

ID=32799540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000413 Ceased WO2004075922A2 (fr) 2003-02-24 2004-02-24 Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisation et lesdits agents de liaison

Country Status (2)

Country Link
FR (1) FR2851471B1 (fr)
WO (1) WO2004075922A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603512A2 (fr) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Nouvelles cyclosporines
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006039164A2 (fr) 2004-09-29 2006-04-13 Amr Technology, Inc. Nouveaux analogues de la cyclosporine et leurs utilisations pharmaceutiques
EP1812037A4 (fr) 2004-10-06 2009-11-11 Amr Technology Inc Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037388A2 (fr) * 1980-03-31 1981-10-07 Institut International De Pathologie Cellulaire Et Moleculaire Formes pharmaceutiques, leur préparation et les compositions qui les contiennent
EP0394989A2 (fr) * 1989-04-28 1990-10-31 Fujisawa Pharmaceutical Co., Ltd. Composés peptidiques, leur préparation et médicaments les renfermant
JP2001206897A (ja) * 2000-01-26 2001-07-31 Nippon Seibutsu Seizai:Kk ハイドロキシプロリン誘導体
FR2836474A1 (fr) * 2002-02-22 2003-08-29 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272253A4 (fr) * 1986-03-07 1990-02-05 Massachusetts Inst Technology Procede pour ameliorer la stabilite des glycoproteines.
RU2002127425A (ru) * 2000-03-15 2004-03-27 Бристоль-Мейерз Сквибб Фарма Компани (Us) Расщепляемые пептидазой целевые противоопухолевые лекарственные средства и их терапевтическое использование
EP1334128A2 (fr) * 2000-11-02 2003-08-13 Maxygen Aps Nouveaux polypeptides $g(b) interferon multimeres

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037388A2 (fr) * 1980-03-31 1981-10-07 Institut International De Pathologie Cellulaire Et Moleculaire Formes pharmaceutiques, leur préparation et les compositions qui les contiennent
EP0394989A2 (fr) * 1989-04-28 1990-10-31 Fujisawa Pharmaceutical Co., Ltd. Composés peptidiques, leur préparation et médicaments les renfermant
JP2001206897A (ja) * 2000-01-26 2001-07-31 Nippon Seibutsu Seizai:Kk ハイドロキシプロリン誘導体
FR2836474A1 (fr) * 2002-02-22 2003-08-29 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GREENWELL DAVID R ET AL: "Peptide-templated saccharide synthesis on a solid support.", ANGEWANDTE CHEMIE (INTERNATIONAL ED. IN ENGLISH), vol. 41, no. 7, 2 April 2002 (2002-04-02), pages 1215 - 1218, XP002291876, ISSN: 0570-0833 *
LIFFERTH, AXEL ET AL: "Synthesis and structure of proline-ring-modified actinomycins of the X-type", ZEITSCHRIFT FUER NATURFORSCHUNG, B: CHEMICAL SCIENCES, CODEN: ZNBSEN; ISSN: 0932-0776, vol. 54, no. 5, 1999, pages 681 - 691, XP001194726 *
POIANI G J ET AL: "CONJUGATES OF CIS-4-HYDROXY-L-PROLINE AND POLY(PEG-LYS), A WATER SOLUBLE POLY(ETHER URETHANE): SYNTHESIS AND EVALUATION OF ANTIFIBROTIC EFFECTS IN VITRO AND IN VIVO", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 5, no. 6, 1 November 1994 (1994-11-01), WASHINGTON, US, pages 621 - 630, XP000484177, ISSN: 1043-1802 *
ROTHBARD J B ET AL: "Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation", NATURE MEDICINE, vol. 6, no. 11, November 2000 (2000-11-01), UNITED STATES, pages 1253 - 1257, XP002291867, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2004075922A2 (fr) 2004-09-10
FR2851471A1 (fr) 2004-08-27
FR2851471B1 (fr) 2006-07-28

Similar Documents

Publication Publication Date Title
WO2004074244A3 (fr) Composes de pyrimidine
WO2003095455A3 (fr) Composes therapeutiques
WO2007146248A3 (fr) Préparations de laquinimod stables
TWI328576B (en) Diketohydrazine derivative compound, medicament containing same as active ingredient
WO2002048147A3 (fr) Composes therapeutiques
WO2003059251A3 (fr) Composes de ciblage d'anticorps
WO2001032646A3 (fr) Nouveaux composes
WO2004014322A3 (fr) Compositions immunomodulatrices, leurs methodes de preparation et utilisation
WO2003084943A3 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutiques en contenant
WO2008006528A3 (fr) Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
CL2004001085A1 (es) Compuestos derivados de quinolil propil piperidina, procedimiento de preparacion; compuesto intermediario; composicion farmaceutica, utiles como agentes microbianos.
AU2003222786A1 (en) Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
WO2002048148A3 (fr) Composes therapeutiques
WO2007021970A3 (fr) Formes pharmaceutiques stables et methodes d'utilisation de celles-ci
EP1619180A4 (fr) ANTAGONISTE DE CaSR
WO2004093800A3 (fr) Derives de thyronamine et analogues et des methodes d'utilisation de ces composes
WO2007030361A3 (fr) Composes de benzimidazole thiophene
WO2007090661A3 (fr) Combinaison de substances actives
WO2007022956A3 (fr) Compositions pharmaceutiques
WO2007075825A3 (fr) Composes lipophiles di (anticancereux), compositions, et procedes associes
WO2005051083A3 (fr) Composes molluscicides et anti-anatifes
WO2005085236A3 (fr) Inhibiteurs de la caspase et leurs utilisations
WO2004087652A3 (fr) Composes d'imidazotriazine
WO2004047724A3 (fr) Composes aryle et heteroaryle a action anti-bacterienne et anti-fongique
TW200621160A (en) Anti-termite agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase